Imperative Care Raises Series E Financing Led by Ally Bridge Group
Imperative Care, a medical technology company based in Campbell, Calif., is focused on developing connected innovations to elevate care for individuals impacted by stroke and other ischemic diseases. The company aims to address specific gaps in treatment and care to make a positive impact across the entire patient journey.
The recently closed Series E financing round, which was oversubscribed, will be utilized to fuel Imperative Cares hypergrowth strategy. The funding will support the companys goal of making better care accessible to more patients by investing in novel technologies and clinical evidence to measure the impact on patient outcomes.
Ally Bridge Group led the financing round, with participation from existing investors such as D1 Capital Partners, AMED Ventures, Bain Capital Life Sciences, Rock Springs Capital Management LP, Innovatus Capital Partners, LLC, and Pura Vida Investments. New investors, including Catalio Capital Management, LP, HealthCor Family Office, Montreux Growth Partners, and INTAI Technology Corp, also participated in the funding.
The total funding raised in this Series E financing round could reach up to $150 million, subject to additional closings at the discretion of the company.
Appointment of Shacey Petrovic to Vice Chair, Board of Directors
Shacey Petrovic has been appointed to the newly created position of Vice Chair of the Board of Directors at Imperative Care. Petrovic, who joined the board in 2023, will focus on strategies to scale the company and bring lifechanging technologies to more patients suffering from stroke and other vascular diseases.
Petrovics experience includes serving on the boards of Exact Sciences, Ambu A/S, and Axena Health. She previously served as President and CEO of Insulet Corporation, a diabetes technology company, where she led the company to serve hundreds of thousands of individuals with diabetes globally.
The companys Chairman and CEO, Fred Khosravi, expressed gratitude for the support of both existing and new investors and emphasized the companys commitment to delivering impactful innovations to patients facing critical medical situations.
